Clinical Trials
3 trialsNCT04138875 2022-06-23
A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
Yale University
Phase 2 Withdrawn
NCT02623920 2017-05-19
S-BR
University of Arizona
Phase 2 Withdrawn
NCT01620229 2014-04-21
Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
Phase 1/2 Withdrawn